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The purpose of this project is to improve clinical 
outcomes in patients transitioning from inpatient 
to outpatient care by optimizing the process that 
primary care pharmacists use to perform 
comprehensive medication reviews.
• Transitions of care from the inpatient to outpatient 
setting is an area of great opportunity for improving 
patient outcomes.
• One prospective cohort study found that 20% of 
patients discharged from the hospital to home 
experienced an adverse event within 3 weeks of 
discharge. Of these adverse events, 66% were 
medication related.1
• Another observational study found that 14% of 
patients had medication discrepancies at 
discharge, and that readmission rates were 
significantly higher in these cases.2,3
• Currently, patients receiving care at our medical 
group are reviewed by a clinical pharmacist 
following hospital discharge if the reason for 
hospitalization is, or medications were changed for 
treatment of: 
• Congestive Heart failure 
• Osteoporosis/fragility fracture 
• Diabetes on insulin 
• Anticoagulation 
• Patient confusion with medications or 
difficulty taking/obtaining them
• Anecdotally our group has reported many resolved 
medication issues and avoided medication adverse 
events since this system was implemented, 
although these interventions have not been 
formally quantified.
• There is not currently a standardized process 
clinical pharmacists use to review medications 
upon hospital  discharge. 
These results suggest that a standardized review 
process conducted via EPIC smart phrases 
increases interventions provided via clinical 
pharmacy review during transitions of care.
Several important confounding factors such as 
seasonal/staffing variation and the unblinded 
nature of this study must be considered when 
interpreting study results.
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• Results from a retrospective chart review and a 
clinical pharmacist satisfaction survey were  
utilized to standardize and optimize our 
transitions of care review process.
Inclusion Criteria:





• The number of interventions/recommendations 
provided by clinical pharmacists to primary care 
providers per transitions of care consult
Secondary Endpoints:
• The time taken by clinical pharmacists to 
complete transitions of care consults 
• Proportion of clinical pharmacist 
recommendations that are implemented 
• 30-day re-hospitalization rates. 
Pharmacist Time per Transitions of Care Consult 
• Results of the initial review (August and 
September 2021) and survey were  utilized 
to make improvements to transitions of care 
review process.
• Interventions implemented thus far include:
• Development of EPIC smart 
phrases to standardize pharmacist 
review process.
• Meeting with the Clinical Support 
Coordinator team to review 
strategies to optimize referrals to 
clinical pharmacy.
• A second retrospective chart 
review was completed 1 month after the 
updated EPIC smart phrases were implemented 
(April 2021) to determine the impact on 
recommended interventions and time spent per 
pharmacist consult. 
Additional Data Collection:
• One more month of data will be added to the 
evidence summarized here to allow 2 months of 
pre and post data.
• 30-day readmission rates post-intervention will 
be evaluated when 30 days have passed from 
the data collection period. This will allow for 
determination of increased interventions or 
readmission rates.
Continued Process Improvement Possibilities:
• Adjusting criteria for PharmD review
• Leverage clinical pharmacy team to continue 
modifying and improving recently created EPIC 
smart phrases
• Continued collaboration with Clinical Support 





































































Post-Intervention: 45 Consults (78% used updated EPIC smart phrases)  
